Main news

 


 

FDA Approves First Pulsed Field Ablation System for AF
FDA Approves First Pulsed Field Ablation System for AF The US Food and Drug Administration (FDA) has approved the PulseSelect Pulsed Field Ablation (PFA) System (Medtronic) for the treatment of both paroxysmal and persistent atrial fibrillation (AF), the manufacturer has announced.


A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic Syndrome
A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic Syndrome A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led to the conceptualization of cardiovascular-kidney-metabolic syndrome. The confluence of metabolic risk factors and chronic kidney disease within cardiovascular-kidney-metabolic syndrome is strongly linked to risk for adverse cardiovascular and kidney outcomes.


Editorial Activity

cardiology book

FDA's Assessment of Currently Marketed ARB drug products
FDA's Assessment of Currently Marketed ARB drug products FDA has worked with manufacturers to swiftly remove angiotensin II receptor blocker (ARB) drug products with impurity levels above interim acceptable limits. Those products have been removed from the market and have been posted in our recall lists for ARB products.


Three or more eggs a week increase your risk of heart disease and early death, study says
Three or more eggs a week increase your risk of heart disease and early death, study says It's been debated for years: Are eggs good or bad for you? People who eat an added three or four eggs a week or 300 milligrams of dietary cholesterol per day, have a higher risk of both heart disease and early death compared with those who eat fewer eggs, new research finds.


e-Cigarettes Linked to Increased Stroke, MI Risk
e-Cigarettes Linked to Increased Stroke, MI Risk Use of electronic cigarettes (e-cigarettes) is linked to a significantly increased risk for "hard" adverse outcomes, such as stroke and myocardial infarction (MI), new research suggests. Among more than 400,000 respondents older than 18 years from the 2016 Behavioral Risk Factor Surveillance System (BRFSS) survey, almost 66,800 reported having ever used e-cigarettes.


INTERNATIONAL YOUNG ACADEMY OF CARDIOLOGY CONGRESS
INTERNATIONAL YOUNG ACADEMY OF CARDIOLOGY CONGRESS INTERNATIONAL YOUNG ACADEMY OF CARDIOLOGY CONGRESS


Personal income may increase risk of heart disease
Personal income may increase risk of heart disease Income levels, if they are unstable, can easily turn into a stressor. However, the volatility of personal income could be having a more serious effect on people's heart health. It is often expected that a person's income will constantly rise until they reach retirement age.


Weight-Adjusted Aspirin Dosing:  Evidence Builds in Primary Prevention
Weight-Adjusted Aspirin Dosing: Evidence Builds in Primary Prevention Low-dose aspirin intended for primary prevention, typically 75 to 100 mg once daily, doesn"t protect against cardiovascular events in persons who weigh at least 70 kg (about 154 pounds), suggests a patient-level analysis of randomized trials that included more than 100,000 patients. But daily aspirin at higher dosages, usually at least 300 mg, was cardioprotective in that group, as was low-dose aspirin in people who weighed less than 70 kg.


New ADA/EASD Guidance on Diabetes: Assess CV Status First
New ADA/EASD Guidance on Diabetes: Assess CV Status First The treatment approach to type 2 diabetes should begin with an assessment of cardiovascular disease (CVD) status, other comorbidities, and patient preferences, according to a draft of the upcoming 2018 joint consensus statement from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD). The final version of the 2018 update to the current 2015 ADA/EASDManagement of Hyperglycemia in Type 2 Diabetes statement (Diabetes Care.2015;38:140-149) will be presented on October 5, 2018 at the EASD annual meeting in Berlin and will be published in Diabetes Care and Diabetologia.